ENDOMETRIOSIS AND FEMALE SEXUAL DYSFUNCTION
Main Article Content
Abstract
Introduction: Endometriosis is a common gynecological disease with painful symptoms
including: dysmenorrhea (60-80%), chronic pelvic pain (30-50%), infertility (30-40%) and
sexual pain (25-40%). Therefore, endometriosis can more or less affect the quality of a
woman’s sex life and sometimes is a direct cause of female sexual dysfunction.
Methods: Studies on endometriosis, the effects of the disease on female sexual function and
treatment methods were collected from PubMed database.
Results: Female sexual dysfunction, mainly sexual pain, is the most commonly described
symptom in cases of endometriosis. Meanwhile, therapies for the pain caused by endometriosis
are controversial about the effectiveness and duration of symptoms.
Discussions: The treatment of symptoms and complications caused by endometriosis
currently has not had a great consensus, showing the important role of clinical experts in
choosing the regimen for the goal of pain relief, reduce fatigue, improve work productivity
and improve quality of life, especially sexual function.
Conclusion: Endometriosis is a disease that affects all aspects of a woman’s life, including
sexual function.
Article Details
Keywords
Endometriosis, female sexual dysfunction.
References
Endocr. Rev. 2019;1:1048–1079.
[2] Pessoa de Farias RM, Lima VF et al.,
Clinical aspects and the quality of life among
women with endometriosis and infertility:
A cross-sectional study. BMC Womens
Health. 2020;12:124.
[3] La Rosa VL, De FP, Quality of life in
women with endometriosis: A narrative
overview. Minerva Med. 2020;111:68–78.
[4] Rush G, Misajon R, Examining subjective
wellbeing and health-related quality of life
in women with endometriosis. Health Care
Women Int. 2018;39:303–321.
[5] Vercellini P, Are combined hormonal
contraceptives the neglected treatment
for symptomatic endometriosis? Fertil.
Steril. 2018;110:61–62.
[6] Vercellini P, Facchin F, Management
of endometriosis: Toward value-based,
cost-effective, affordable care. J. Obstet.
Gynaecol. Can. 2018;40:726–749.e10.
[7] Vercellini P, Donati A, A stepped-care
approach to symptomatic endometriosis
management: A participatory research
initiative. Fertil. Steril.2018;109:1086–1096.
[8] Reis FM, Coutinho LM, Vannuccini S et
al., Progesterone receptor ligands for the
treatment of endometriosis: The mechanisms
behind therapeutic success and failure. Hum.
Reprod. Updat. 2020;26:565–585.
[9] Surrey E, Taylor HS, Long-term outcomes
of elagolix in women with endometriosis:
Results from two extension studies. Obstet.
Gynecol. 2018;132:147–160.
[10] Osuga Y, Seki Y, Tanimoto M et al., an oral
gonadotropin-releasing hormone receptor
antagonist, reduces endometriosis-associated
pain in a dose-response manner: A randomized,
double-blind, place-bo-controlled study. Fertil.
Steril. 2021;115:397–405.
[11] Donnez J, Taylor HS, Treatment of endometriosis-associated pain with linzagolix,
an oral gonadotropin-releasing hormoneantagonist: A randomized clinical trial. Fertil.
Steril. 2020;114:44–55.
[12] Pohl O, Marchand L, Bell D et al., Effects
of combined GnRH receptor antagonist
linzagolix and hormonal add-back therapy on
vaginal bleeding—Delayed add-back onset
does not improve bleeding pattern. Reprod.
Sci. 2020;27:988–995.
[13] Taylor HS, Dun EC, Chwalisz K, Clinical
evaluation of the oral gonadotropinreleasing hormone-antagonist elagolix for
the management of endometriosis-associated
pain. Pain Manag. 2019;9:497–515.
[14] Donnez O, Donnez J, Gonadotropinreleasing hormone antagonist (linzagolix): A
new therapy for uterine adenomyosis. Fertil.
Steril. 2020;114:640–645.
[15] Barra F, Scala C, Ferrero S, Elagolix sodium
for the treatment of women with moderate to
severe endometriosis-associated pain. Drugs
Today. 2019;55:237–246.89
[16] Lamb YN, Elagolix: First global
approval. Drugs. 2018;78:1501–1508.
[17] Archer DF, Soliman AM, Agarwal SK et al.,
Elagolix in the treatment of endometriosis:
impact beyond pain symptoms. Ther Adv
Reprod Health. 2020;14:2633494120964517.
Published 2020 Dec 1.
[18] As-Sanie S, Becker CM, Efficacy and
safety of relugolix combination therapy
in women with endometriosis-associated
pain: Phase 3 randomized, double-blind,
placebo-controlled study (spirit 2) Fertil.
Steril. 2020;114:e77.
[19] Donnez J, Dolmans MM, Endometriosis
and Medical Therapy: From Progestogens
to Progesterone Resistance to GnRH
Antagonists: A Review. J Clin Med.
2021;10(5):1085. Published 2021 Mar 5.
[20] Awad E, Ahmed HAH, Yousef A et al.,
Efficacy of exercise on pelvic pain and
posture associated with endometriosis:
Within subject design. J. Phys. Ther.
Sci. 2017;29:2112–2115.
[21] Leonardi M, Horne AW, Selfmanagement strategies to consider to
combat endometriosis symptoms during
the COVID-19 pandemic. Hum. Reprod.
Open. 2020;1:hoaa028.
[22] Mińko A, Turoń-Skrzypińska A, Rył A et al.,
Endometriosis-A Multifaceted Problem of a
Modern Woman. Int J Environ Res Public
Health. 2021;18(15):8177. Published 2021
Aug 2.
[23] Stanton AM, Handy AB, Meston CM, The
Effects of Exercise on Sexual Function in
Women. Sex. Med. Rev. 2018;6:548–557.